New Delhi, Feb. 24 -- India's drug regulator is rolling back low-risk procedural requirements in clinical research and exports while strengthening enforcement on manufacturing quality, signalling a more risk-based approach to regulation.

The Central Drugs Standard Control Organisation (CDSCO) will withdraw the requirement for export No-Objection Certificates (NOCs) for pharmaceutical shipments to stringent regulatory authority (SRA) markets, including the US, Europe, the UK, Japan, Canada and Australia.

Exporters will now need only an automated acknowledgement, with the change to be notified shortly.

Faster Approvals, Lower Compliance Burden

The move follows earlier decisions to eliminate test licence requirements for activities up to...